173 related articles for article (PubMed ID: 32214520)
1. Efficacy of Low-Dose Aripiprazole for Treatment of Psychotic Symptoms in a Patient with 22q11.2 Deletion Syndrome.
Kontoangelos K; Lazaratou E; Economou M; Yiannopoulou KG; Papageorgiou CC
Psychopharmacol Bull; 2020 Mar; 50(1):35-39. PubMed ID: 32214520
[TBL] [Abstract][Full Text] [Related]
2. The interaction between neurocognitive functioning, subthreshold psychotic symptoms and pharmacotherapy in 22q11.2 deletion syndrome: A longitudinal comparative study.
Weinberger R; Weisman O; Guri Y; Harel T; Weizman A; Gothelf D
Eur Psychiatry; 2018 Feb; 48():20-26. PubMed ID: 29331595
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness and tolerability of pharmacotherapy for psychosis in 22q11.2 Deletion Syndrome: A systematic review.
Tanham M; Chen R; Warren N; Heussler H; Scott JG
Aust N Z J Psychiatry; 2024 May; 58(5):393-403. PubMed ID: 38383990
[TBL] [Abstract][Full Text] [Related]
4. [Neurocognitive and psychiatric management of the 22q11.2 deletion syndrome].
Demily C; Rossi M; Schneider M; Edery P; Leleu A; d'Amato T; Franck N; Eliez S
Encephale; 2015 Jun; 41(3):266-73. PubMed ID: 25523123
[TBL] [Abstract][Full Text] [Related]
5. Is Aripiprazole Useful for Treatment of Psychotic Symptoms in a Patient With 22q11.2 Deletion Syndrome?: A Case Series.
Berardelli I; Cifrodelli M; Giuliani C; Antonelli G; Putotto C; Pulvirenti F; Pompili M
J Clin Psychopharmacol; 2023 Jul-Aug 01; 43(4):384-386. PubMed ID: 37335196
[No Abstract] [Full Text] [Related]
6. Risk factors and the evolution of psychosis in 22q11.2 deletion syndrome: a longitudinal 2-site study.
Gothelf D; Schneider M; Green T; Debbané M; Frisch A; Glaser B; Zilkha H; Schaer M; Weizman A; Eliez S
J Am Acad Child Adolesc Psychiatry; 2013 Nov; 52(11):1192-1203.e3. PubMed ID: 24157393
[TBL] [Abstract][Full Text] [Related]
7. Clinical and cognitive risk factors for psychotic symptoms in 22q11.2 deletion syndrome: a transversal and longitudinal approach.
Schneider M; Schaer M; Mutlu AK; Menghetti S; Glaser B; Debbané M; Eliez S
Eur Child Adolesc Psychiatry; 2014 Jun; 23(6):425-36. PubMed ID: 23999732
[TBL] [Abstract][Full Text] [Related]
8. Biological effects of COMT haplotypes and psychosis risk in 22q11.2 deletion syndrome.
Gothelf D; Law AJ; Frisch A; Chen J; Zarchi O; Michaelovsky E; Ren-Patterson R; Lipska BK; Carmel M; Kolachana B; Weizman A; Weinberger DR
Biol Psychiatry; 2014 Mar; 75(5):406-13. PubMed ID: 23992923
[TBL] [Abstract][Full Text] [Related]
9. Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome.
Vorstman JA; Breetvelt EJ; Duijff SN; Eliez S; Schneider M; Jalbrzikowski M; Armando M; Vicari S; Shashi V; Hooper SR; Chow EW; Fung WL; Butcher NJ; Young DA; McDonald-McGinn DM; Vogels A; van Amelsvoort T; Gothelf D; Weinberger R; Weizman A; Klaassen PW; Koops S; Kates WR; Antshel KM; Simon TJ; Ousley OY; Swillen A; Gur RE; Bearden CE; Kahn RS; Bassett AS;
JAMA Psychiatry; 2015 Apr; 72(4):377-85. PubMed ID: 25715178
[TBL] [Abstract][Full Text] [Related]
10. The Effectiveness and Safety of Antipsychotic and Antidepressant Medications in Individuals with 22q11.2 Deletion Syndrome.
Dori N; Green T; Weizman A; Gothelf D
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):83-90. PubMed ID: 26131914
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of clozapine in treatment-resistant psychotic patients with DiGeorge syndrome (22q11.2 deletion syndrome): a case series.
Berardelli I; Cifrodelli M; Giuliani C; Antonelli G; Putotto C; Pulvirenti F; Pompili M
Int Clin Psychopharmacol; 2024 Jul; 39(4):284-287. PubMed ID: 37824335
[TBL] [Abstract][Full Text] [Related]
12. Attention deficit hyperactivity disorder symptoms as antecedents of later psychotic outcomes in 22q11.2 deletion syndrome.
Niarchou M; Chawner SJRA; Fiksinski A; Vorstman JAS; Maeder J; Schneider M; Eliez S; Armando M; Pontillo M; Vicari S; McDonald-McGinn DM; Emanuel BS; Zackai EH; Bearden CE; Shashi V; Hooper SR; Owen MJ; Gur RE; Wray NR; van den Bree MBM; Thapar A;
Schizophr Res; 2019 Feb; 204():320-325. PubMed ID: 30093352
[TBL] [Abstract][Full Text] [Related]
13. Elevated Proinflammatory Markers in 22q11.2 Deletion Syndrome Are Associated With Psychosis and Cognitive Deficits.
Mekori-Domachevsky E; Taler M; Shoenfeld Y; Gurevich M; Sonis P; Weisman O; Weizman A; Gothelf D
J Clin Psychiatry; 2017; 78(9):e1219-e1225. PubMed ID: 29141125
[TBL] [Abstract][Full Text] [Related]
14. Mapping Subcortical Brain Alterations in 22q11.2 Deletion Syndrome: Effects of Deletion Size and Convergence With Idiopathic Neuropsychiatric Illness.
Ching CRK; Gutman BA; Sun D; Villalon Reina J; Ragothaman A; Isaev D; Zavaliangos-Petropulu A; Lin A; Jonas RK; Kushan L; Pacheco-Hansen L; Vajdi A; Forsyth JK; Jalbrzikowski M; Bakker G; van Amelsvoort T; Antshel KM; Fremont W; Kates WR; Campbell LE; McCabe KL; Craig MC; Daly E; Gudbrandsen M; Murphy CM; Murphy DG; Murphy KC; Fiksinski A; Koops S; Vorstman J; Crowley TB; Emanuel BS; Gur RE; McDonald-McGinn DM; Roalf DR; Ruparel K; Schmitt JE; Zackai EH; Durdle CA; Goodrich-Hunsaker NJ; Simon TJ; Bassett AS; Butcher NJ; Chow EWC; Vila-Rodriguez F; Cunningham A; Doherty J; Linden DE; Moss H; Owen MJ; van den Bree M; Crossley NA; Repetto GM; Thompson PM; Bearden CE
Am J Psychiatry; 2020 Jul; 177(7):589-600. PubMed ID: 32046535
[TBL] [Abstract][Full Text] [Related]
15. Riluzole effectively treats psychotic symptoms and improves cognition in 22q11.2 deletion syndrome: A clinical case.
Vingerhoets C; Tse DHY; van Amelsvoort T
Eur J Med Genet; 2019 Aug; 62(8):103705. PubMed ID: 31229682
[TBL] [Abstract][Full Text] [Related]
16. [An Adult Case of 22q11.2 Deletion Syndrome with Congenital Abnormalities and Neurodevelopmental Disorders, Which Remained Undiagnosed Until Presentation of Auditory Hallucinations].
Tamune H; Nishimura F; Koshiyama D; Yamada K; Kondo S; Kano Y; Kasai K
Seishin Shinkeigaku Zasshi; 2017; 119(1):9-16. PubMed ID: 30629863
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and side effects of psychopharmacotherapy in individuals with 22q11.2 deletion syndrome with comorbid psychiatric disorders: a systematic review.
Mosheva M; Korotkin L; Gur RE; Weizman A; Gothelf D
Eur Child Adolesc Psychiatry; 2020 Aug; 29(8):1035-1048. PubMed ID: 30949827
[TBL] [Abstract][Full Text] [Related]
18. Predicting Cognition and Psychosis in Young Adults With 22q11.2 Deletion Syndrome.
Antshel KM; Fremont W; Ramanathan S; Kates WR
Schizophr Bull; 2017 Jul; 43(4):833-842. PubMed ID: 27798222
[TBL] [Abstract][Full Text] [Related]
19. Stimulant treatment effectiveness, safety and risk for psychosis in individuals with 22q11.2 deletion syndrome.
Basel D; Mosheva M; Maeder J; Schneider M; Shani S; Weinberger R; Eliez S; Gothelf D
Eur Child Adolesc Psychiatry; 2022 Sep; 31(9):1367-1375. PubMed ID: 33871687
[TBL] [Abstract][Full Text] [Related]
20. Association between prematurity and the evolution of psychotic disorders in 22q11.2 deletion syndrome.
Midbari Kufert Y; Nachmani A; Nativ E; Weizman A; Gothelf D
J Neural Transm (Vienna); 2016 Dec; 123(12):1491-1497. PubMed ID: 27517838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
